New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07541534
First seen Apr 24, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. The study focuses on certain ovarian and related cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chongqing Cancer Hospital
Chongqing, China
-
Hubei Cancer Hospital
Wuhan, China
-
Jinan Central Clinical College of Shandong First Medical University
Jinan, China
-
Obstetris &Gynecology Hospital of Fudan University
Shanghai, China
-
Shandong Cancer Hospital
Jinan, China
Conditions
Explore the condition pages connected to this study.